Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial

被引：0

作者：

Tetsu Hayashida

Hiromitsu Jinno

Katsuaki Mori

Hiroki Sato

Akira Matsui

Takashi Sakurai

Hiroaki Hattori

Shin Takayama

Masahiro Wada

Maiko Takahashi

Hirohito Seki

Tomoko Seki

Aiko Nagayama

Akiko Matsumoto

Yuko Kitagawa

机构：

[1] Keio University School of Medicine,Department of Surgery

[2] Teikyo University School of Medicine,Department of Surgery

[3] Hino Municipal Hospital,Department of Surgery

[4] Mito Red Cross Hospital,Department of Surgery

[5] National Hospital Organization Tokyo Medical Center,Department of Surgery

[6] JCHO Saitama Medical Center,Division of Surgery

[7] Federation of National Public Service Personnel Mutual Aid Associations,Department of Surgery

[8] Tachikawa Hospital,Department of surgery

[9] Tokyo Dental College Ichikawa General Hospital,Department of Surgery

[10] Sanokousei general hospital,undefined

来源：

BMC Cancer | / 18卷

关键词：

Breast cancer; Eribulin; Phase II trial;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial
Hayashida, Tetsu
Jinno, Hiromitsu
Mori, Katsuaki
Sato, Hiroki
Matsui, Akira
Sakurai, Takashi
Hattori, Hiroaki
Takayama, Shin
Wada, Masahiro
Takahashi, Maiko
Seki, Hirohito
Seki, Tomoko
Nagayama, Aiko
Matsumoto, Akiko
Kitagawa, Yuko
BMC CANCER, 2018, 18
[2] A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes
Kosei Kimura
Mitsuhiko Iwamoto
Satoru Tanaka
Daigo Yamamoto
Katsuhide Yoshidome
Hiroyuki Ogura
Risa Terasawa
Nobuki Matsunami
Yuko Takahashi
Toshikatsu Nitta
Takashi Morimoto
Hiroya Fujioka
Kanako Kawaguchi
Kazuhisa Uchiyama
Cancer Chemotherapy and Pharmacology, 2018, 81 : 923 - 933
[3] A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes
Kimura, Kosei
Iwamoto, Mitsuhiko
Tanaka, Satoru
Yamamoto, Daigo
Yoshidome, Katsuhide
Ogura, Hiroyuki
Terasawa, Risa
Matsunami, Nobuki
Takahashi, Yuko
Nitta, Toshikatsu
Morimoto, Takashi
Fujioka, Hiroya
Kawaguchi, Kanako
Uchiyama, Kazuhisa
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (05) : 923 - 933
[4] Eribulin for patients with metastatic extramammary Paget disease: Study protocol for a single-arm phase II trial
Maeda, Takuya
Yanagi, Teruki
Tokuchi, Keiko
Funakoshi, Takeru
Horie, Nao
Isoe, Toshiyuki
Ito, Yoichi M.
Sato, Norihiro
Ujiie, Hideyuki
EXPERIMENTAL DERMATOLOGY, 2024, 33 (01)
[5] Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)
De Angelis, C.
Bruzzese, D.
Bernardo, A.
Baldini, E.
Leo, L.
Fabi, A.
Gamucci, T.
De Placido, P.
Poggio, F.
Russo, S.
Forestieri, V
Lauria, R.
De Santo, I
Michelotti, A.
Del Mastro, L.
De Laurentiis, M.
Giuliano, M.
De Placido, S.
Arpino, G.
ESMO OPEN, 2021, 6 (02)
[6] Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14]
Hasler-Strub, Ursula
Mueller, Andreas
Li, Qiyu
Thuerlimann, Beat
Ribi, Karin
Gerber, Stefan
von Moos, Roger
Fehr, Mathias
Rochlitz, Christoph
Zaman, Khalil
Aebi, Stefan
Hochstrasser, Andreas
Gick, Ute
Baertschi, Daniela
Greuter, Stefan
Schreiber, Alexander
Caspar, Clemens B.
Trojan, Andreas
Condorelli, Rosaria
Ruhstaller, Thomas
JOURNAL OF GERIATRIC ONCOLOGY, 2023, 14 (01)
[7] Capecitabine and oxaliplatin in combination as first- or second-line therapy for metastatic breast cancer: a Wisconsin Oncology Network trial
Njiaju, U. O.
Tevaarwerk, A. J.
Kim, K.
Chang, J. E.
Hansen, R. M.
Champeny, T. L.
Traynor, A. M.
Meadows, S.
Van Ummersen, L.
Powers, K.
Stewart, J. A.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (03) : 613 - 618
[8] Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study
Ortega, Vanesa
Anton, Antonio
Garau, Isabel
Afonso, Nomia
Calvo, Lourdes
Fernandez, Yolanda
Martinez-Garcia, Maria
Blanco, Esperanza
Zamora, Pilar
Garcia, Mirta
Juan Illarramendi, Jose
Rodriguez Sanchez, Csar Augusto
Sampayo, Miguel
Aguirre, Elena
Manuel Perez-Garcia, Jose
Cortes, Javier
Llombart-Cussac, Antonio
CLINICAL BREAST CANCER, 2019, 19 (02) : 105 - 112
[9] Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial
Inoue, Kenichi
Ninomiya, Jun
Saito, Tsuyoshi
Okubo, Katsuhiko
Nakakuma, Takashi
Yamada, Hirofumi
Kimizuka, Kei
Higuchi, Tohru
INVESTIGATIONAL NEW DRUGS, 2019, 37 (03) : 538 - 547
[10] Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial
Zhang, Changgong
Chen, Jianhua
Wu, Huijuan
Wang, Jun
Gao, Liying
Zhao, Jun
Sun, Yan
Jia, Zhongyao
Mu, Xinlin
Bai, Chunmei
Wang, Rui
Wu, Kailiang
Liu, Qiang
Shi, Yuankai
CANCER PATHOGENESIS AND THERAPY, 2024, 2 (04): : 268 - 275

← 1 2 3 4 5 →